15 April 2025NewsEuropeEoin Martyn & Hannah Garvey
Failure to make findings of fact adds twist to battle over Eliquis in Ireland
A new High Court judge will be tasked with the “massive decision” on the plausibility of Bristol Myers Squibb’s key anticoagulant patent, following its appeal over failures in the previous trial, say Eoin Martyn and Hannah Garvey of Taylor Wessing.
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
10 April 2025 Pharma giant dodges threat as US judge dismisses monopoly claims over its blockbuster cancer drug | FDA approves new treatment combo for advanced colorectal cancer.
9 May 2023 Decision addresses issue of plausibility in invalidation verdict |
Case marks first time that Court of Appeal judges held a patent with a single claim to a pharma compound invalid.
6 September 2021 In a victory for Bristol-Myers Squibb and Pfizer, the US Court of Appeals for the Federal Circuit has affirmed the validity of a pair of patents covering blood clot treatment, Eliquis.